Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.

Abstract:

:The treatment of established veno-occlusive disease (VOD) of the liver with tissue plasminogen activator (tPA) has been disappointing. In attempts to improve upon these results we identified a subgroup of patients with consistently elevated bilirubin levels who did not meet conventional criteria for VOD (Susp VOD) but who had a significant risk of later developing clinical VOD. In January 1994 we began to treat patients who developed Susp VOD with tPA rather than waiting until they developed clinical VOD. We now report on the results of the first 37 patients who ultimately developed clinical VOD and received tPA therapy prior to Susp VOD, or at the time they had established VOD. Significant bleeding complications occurred in 13 (35%) patients but resolved with discontinuation of therapy in all but one. We found that patients treated early in the course of hepatotoxicity prior to the development of overt VOD had a significantly higher response rate and 100 day survival than patients treated at the time of established VOD. Given the poor results seen in treating late VOD, we suggest that early treatment with tPA may improve the outcome in patients who develop signs of hepatotoxicity following marrow transplantation.

journal_name

Bone Marrow Transplant

authors

Schriber J,Milk B,Shaw D,Christiansen N,Baer M,Slack J,Tezcan H,Wetzler M,Herzig G

doi

10.1038/sj.bmt.1702069

subject

Has Abstract

pub_date

1999-12-01 00:00:00

pages

1311-4

issue

12

eissn

0268-3369

issn

1476-5365

journal_volume

24

pub_type

临床试验,杂志文章
  • Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.

    abstract::PBSCs are usually mobilized using G-CSF with or without chemotherapy. With the emergence of newer mobilizing agents, predicting poor mobilization may allow early intervention and prevent the costs and complications associated with remobilization. We retrospectively evaluated a cohort of 1556 patients seen between Janu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.236

    authors: Sinha S,Gastineau D,Micallef I,Hogan W,Ansell S,Buadi F,Dingli D,Dispenzieri A,Gertz M,Greiner C,Hayman S,Inwards D,Johnston P,Lacy M,Litzow M,Porrata L,Winters JL,Kumar S

    更新日期:2011-07-01 00:00:00

  • Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.

    abstract::We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity condi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705248

    authors: Bregni M,Fleischhauer K,Bernardi M,Pescarollo A,Guggiari E,Lunghi F,Deola S,Scaramuzza S,Re F,Setola E,Monari M,Mazzi B,Servida P,Corradini P,Peccatori J

    更新日期:2006-02-01 00:00:00

  • Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.

    abstract::Recombinant human (rHu) G-CSF has been widely used to treat neutropenia and mobilize PBPCs for their autologous and allogeneic transplantation. It shortens neutropenia and thus reduces the frequency of neutropenic fever. We compared the efficiency of glycosylated rHu and non-glycosylated Hu G-CSF in mobilizing hematop...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.150

    authors: Ria R,Gasparre T,Mangialardi G,Bruno A,Iodice G,Vacca A,Dammacco F

    更新日期:2010-02-01 00:00:00

  • Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.

    abstract::Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patient on long-term amiodarone who developed biopsy-proven drug-indu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703039

    authors: Bhagat R,Sporn TA,Long GD,Folz RJ

    更新日期:2001-05-01 00:00:00

  • Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

    abstract::Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2016.364

    authors: Le Bris Y,Guillaume T,Ménard A,Illiaquer M,Martin J,Malard S,Duquesne A,Peterlin P,Debord C,Robillard N,Eveillard M,Wuillème S,Delaunay J,Mohty M,Garnier A,Moreau P,Béné MC,Chevallier P

    更新日期:2017-06-01 00:00:00

  • Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

    abstract::The application of myeloablative Allo-SCT is limited by its associated morbidity and mortality. Reduced-intensity conditioning regimens attempt to diminish these, but are associated with a higher risk of disease relapse. Given the evidence of activity of clofarabine and cytarabine in myelodysplastic syndrome/acute mye...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2008.423

    authors: Martin MG,Uy GL,Procknow E,Stockerl-Goldstein K,Cashen A,Westervelt P,Abboud CN,Augustin K,Luo J,DiPersio JF,Vij R

    更新日期:2009-07-01 00:00:00

  • Portal vein thrombosis after hematopoietic cell transplantation: frequency, treatment and outcome.

    abstract::Patients who develop veno-occlusive disease (VOD) of the liver may have low plasma levels of the natural anticoagulants protein C and antithrombin III, but large vessel thromboses are not commonly reported in these patients. We reviewed the records of 1847 consecutive patients for evidence of portal vein thrombosis. E...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703368

    authors: Kikuchi K,Rudolph R,Murakami C,Kowdley K,McDonald GB

    更新日期:2002-02-01 00:00:00

  • Prenatal HLA-matching to determine suitability for allogeneic bone marrow transplantation.

    abstract::For several haematological malignancies, allogeneic stem cell transplantation is the treatment of choice. In most cases an HLA-identical sibling is required. If the mother of a patient is pregnant, cord blood from a related donor, which can be used for stem cell transplantation, might be obtainable in the near future....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702219

    authors: van den Berg H,Verjaal M,Boer K,Lardy NM

    更新日期:2000-03-01 00:00:00

  • SCT in Jehovah's Witnesses: the bloodless transplant.

    abstract::Auto-SCT and Allo-SCT are procedures conventionally associated with intensive transfusion support. This dependence has historically prevented SCT in individuals with religious or personal objections to transfusion. More recently, a growing body of literature supports the feasibility of 'bloodless transplants': SCT wit...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2008.5

    authors: Sloan JM,Ballen K

    更新日期:2008-05-01 00:00:00

  • Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis.

    abstract::We prospectively studied absolute lymphocyte (ALC) and monocyte counts (AMC), lymphocyte subsets and proliferative in vitro responses to mitogen and antigen in 12 patients with AL-amyloidosis (AL) undergoing autologous blood stem cell transplantation (SCT) with high-dose i.v. melphalan. Myeloid and lymphoid recovery (...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703298

    authors: Akpek G,Lenz G,Lee SM,Sanchorawala V,Wright DG,Colarusso T,Waraska K,Lerner A,Vosburgh E,Skinner M,Comenzo RL

    更新日期:2001-12-01 00:00:00

  • First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.

    abstract::Extragonadal germ cell tumors are classified according to the staging system of the International Germ Cell Cancer Collaborative Group (IGCCCG). The 5-year overall and disease-free survival rates for poor prognosis patients are 41 and 48%, respectively after standard-dose chemotherapy. We report the experience of the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704704

    authors: Rosti G,De Giorgi U,Wandt H,Lioure B,Leyvraz S,Kolbe K,Papiani G,Ballardini M,Kulekci A,Demirer T,Solid Tumours Working Party.

    更新日期:2004-12-01 00:00:00

  • The bare lymphocyte syndrome.

    abstract::The bare lymphocyte syndrome is a combined immunodeficiency resulting from the lack of expression of either class I or class II HLA antigens at the cell surface. The main clinical manifestations are infections of the respiratory or the digestive tract. The immunodeficiency involves the absence of antibody formation an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Touraine JL,Marseglia GL,Betuel H,Souillet G,Gebuhrer L

    更新日期:1992-01-01 00:00:00

  • Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions.

    abstract::The indolent non-Hodgkin's lymphomas are theoretically curable through allogeneic haematopoietic stem cell transplantation (allo-HSCT). The applicability of standard conditioning allo-HSCT is, however, restricted by its toxicity. Recently, reduced-intensity conditioning regimens have demonstrated efficacy with signifi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703898

    authors: Ho AY,Devereux S,Mufti GJ,Pagliuca A

    更新日期:2003-04-01 00:00:00

  • Complete heart block in association with graft-versus-host disease.

    abstract::An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701038

    authors: Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

    更新日期:1998-01-01 00:00:00

  • Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

    abstract::In this study, outcomes for 575 adult ALL patients aged ≥45 years who underwent first allo-SCT in CR were analyzed according to the type of conditioning regimen (myeloablative conditioning (MAC) for 369 patients vs reduced-intensity conditioning (RIC) for 206 patients). Patients in the RIC group were older (median age...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2013.68

    authors: Tanaka J,Kanamori H,Nishiwaki S,Ohashi K,Taniguchi S,Eto T,Nakamae H,Minagawa K,Miyamura K,Sakamaki H,Morishima Y,Kato K,Suzuki R,Nishimoto N,Oba K,Masauzi N

    更新日期:2013-11-01 00:00:00

  • Allogeneic marrow transplantation using T cell depletion for patients with juvenile chronic myelogenous leukemia without HLA-identical siblings.

    abstract::Six children with clinical and hematologic features of juvenile chronic myelogenous leukemia (JCML) underwent bone marrow transplantation (BMT) using T cell-depleted marrow from non-HLA-matched related or closely HLA-matched unrelated donors. Patient ages ranged from 1.2 to 5 years. Four patients received cytoreductiv...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bunin NJ,Casper JT,Lawton C,Murray K,Camitta BM,Greenwood M,Geil J,Ash RC

    更新日期:1992-02-01 00:00:00

  • Relapse after allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia: cytogenetic analysis of 24 patients.

    abstract::One hundred patients with chronic myeloid leukemia (CML) submitted to bone marrow transplantation (BMT) were included in a cooperative cytogenetic study. Relapse (defined on the basis of hematological and cytogenetic findings) occurred in 24 (24%) patients at different intervals after BMT. In 18 of these patients (stu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zaccaria A,Rosti G,Sessarego M,Frassoni F,Marmont A,Galimberti M,Baronciani D,Filippetti A,Di Bartolomeo P,Di Girolamo G

    更新日期:1988-09-01 00:00:00

  • T cell tolerance after bone marrow transplantation in mice.

    abstract::This article provides a brief overview of T cell tolerance induction in the thymus, using parent----F1 bone marrow (BM) chimeras as a model. Although intrathymic tolerance is controlled largely by BM-derived cells, experiments with BM chimeras suggest that thymic epithelial cells can make a major contribution to toler...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Sprent J,Kosaka H,Gao EK

    更新日期:1992-01-01 00:00:00

  • Evaluation of a monoclonal IgM antibody for purging of bone marrow for autologous transplantation.

    abstract::A monoclonal antibody of the IgM class, reacting with the CD9 (p24) antigen is described. The antibody (FMC27) is cytotoxic against cells of the common type of acute lymphoblastic leukaemia (c-ALL), giving killing at higher dilutions than an IgG antibody (FMC8) against the same antigen. FMC27 and FMC8 recognise differ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zola H,Potter A,Neoh SH,Juttner CA,Haylock DN,Rice AM,Favaloro EJ,Kabral A,Bradstock KF

    更新日期:1987-02-01 00:00:00

  • Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.

    abstract::We performed quantitative PCR-based serial chimerism testing of whole blood (WB) and CD3+ cells and retrospectively correlated the results of chimerism tests and the risk of graft loss in children undergoing transplant for non-malignant disorders. Twenty-four children were included in this study. All patients initiall...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.89

    authors: Ozyurek E,Cowan MJ,Koerper MA,Baxter-Lowe LA,Dvorak CC,Horn BN

    更新日期:2008-07-01 00:00:00

  • Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma.

    abstract::Fifteen patients with stage II-III multiple myeloma were intended to undergo two sequential cycles of myeloablative chemoradiotherapy with autologous bone marrow or blood stem cell transplantation after response to primary induction chemotherapy. BM grafts were used in 13 of the 15 first transplants whereas PBSC were ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Björkstrand B,Ljungman P,Bird JM,Samson D,Gahrton G

    更新日期:1995-03-01 00:00:00

  • First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (

    abstract::Thalidomide-dexamethasone therapy was given in patients (<61 years) with previously untreated symptomatic multiple myeloma. The aim of this study was to assess the efficacy and toxicity of this combination as first-line therapy, and to determine its effect on stem cell collection and engraftment. During first-line the...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究,收录出版

    doi:10.1038/sj.bmt.1705050

    authors: Abdelkefi A,Torjman L,Ben Romdhane N,Ladeb S,El Omri H,Ben Othman T,Elloumi M,Bellaj H,Lakhal A,Jeddi R,Aissaouï L,Saad A,Hsaïri M,Boukef K,Dellagi K,Ben Abdeladhim A

    更新日期:2005-08-01 00:00:00

  • Circulating basic fibroblast growth factor declines during Cy/TBI bone marrow transplantation.

    abstract::Basic fibroblast growth factor (bFGF) inhibits radiation-induced apoptosis, and radioprotects haematopoietic, cartilage growth plate, pulmonary and gastrointestinal tissues. Conversely, chronic overexpression of bFGF may promote fibrosis. We measured the endogenous circulating bFGF in blood of patients undergoing cond...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701778

    authors: Okunieff P,Barrett AJ,Phang SE,Li A,Constine LS,Williams JP,Rubin P,Wang X,Wu T,Chen Y,Ding I

    更新日期:1999-06-01 00:00:00

  • Circulating stem cell autografts.

    abstract::The role of autologous bone marrow transplantation in the treatment of malignant disease is currently being evaluated. The peripheral blood represents an alternative source of haemopoietic progenitors and the use of circulating rather than bone marrow stem cells permits autografting in patients with infiltrated bone m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Bell AJ,Hamblin TJ,Oscier DG

    更新日期:1986-12-01 00:00:00

  • Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.

    abstract::We report an 11-year old female with myelodysplastic (refractory anemia with excess of blasts) presentation of Fanconi anemia. After failure of initial chemotherapy with low doses of 6-mercaptopurine and prednisolone she underwent allogeneic bone marrow transplantation (BMT) from her HLA-matched sibling. Busulfan 8 mg...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700662

    authors: Maschan AA,Kryzanovskii OI,Yourlova MI,Skorobogatova EV,Pashanov ED,Potapova YE,Timonova LA,Bogatcheva NY,Samochatova EV,Roumjantzev AG

    更新日期:1997-02-01 00:00:00

  • Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature.

    abstract::Progressive multifocal leukoencephalopathy (PML) is a rare subacute demyelinating disorder of the central nervous system (CNS) caused by the DNA JC human polyomavirus. In immunocompromised hosts, PML is caused by reactivation of a latent infection rather than de novo primary exposure. PML in the setting of hematopoiet...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705548

    authors: Kharfan-Dabaja MA,Ayala E,Greene J,Rojiani A,Murtagh FR,Anasetti C

    更新日期:2007-01-01 00:00:00

  • Effects of incubation temperature and time after thawing on viability assessment of peripheral hematopoietic progenitor cells cryopreserved for transplantation.

    abstract::Three widely used viability assessments were compared: (1) membrane integrity of nucleated cells using trypan blue (TB) exclusion and a fluorometric membrane integrity assay (SYTO 13 and propidium iodide), (2) enumeration of viable CD34+ cells, and (3) clonogenic assay (granulocyte-macrophage colony-forming units, CFU...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704247

    authors: Yang H,Acker JP,Cabuhat M,McGann LE

    更新日期:2003-11-01 00:00:00

  • Oral protein intake and the risk of acute graft-versus-host disease after allogeneic marrow transplantation.

    abstract::The possibility that antigenically active protein macromolecules affect the risk of developing acute graft-versus-host disease (aGVHD) was investigated in a cohort of patients who underwent allogeneic marrow transplantation for hematologic malignancy (n = 575). Daily records of food intake from transplant through disc...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Cheney CL,Weiss NS,Fisher LD,Sanders JE,Davis S,Worthington-Roberts B

    更新日期:1991-09-01 00:00:00

  • Risk of relapse in patients receiving azithromycin after allogeneic HSCT.

    abstract::Following publication of the ALLOZITHRO trial, the FDA released a safety announcement warning that azithromycin should not be given long-term to prevent BOS in patients with a blood or lymph cancer who have undergone allogeneic HSCT. Our site typically initiated azithromycin when patients were diagnosed with BOS post-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01095-8

    authors: Kutzke JL,Merten JA,Taraba JL,Mara KC,Shah MV,Hashmi SK,Patnaik MM,Litzow MR,Hogan WJ,Alkhateeb HB

    更新日期:2020-10-31 00:00:00

  • Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.

    abstract::Receipt of hematopoietic cell transplantation (HCT) can improve overall survival in older patients with intermediate or high-risk acute myeloid leukemia (AML); however, utilization of HCT is poor. It is important to understand the factors that affect the receipt of HCT in a real-world setting among the older patients....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0164-y

    authors: Bhatt VR,Chen B,Gyawali B,Lee SJ

    更新日期:2018-10-01 00:00:00